Graybug Vision said yesterday that it launched the first clinical trial of its lead product, GB-102, in patients with wet age-related macular degeneration. The two-part study is slated to evaluate patients being treated with available intravitreal anti-VEGF agents who are later switched over to just GB-102. The first part of the study will evaluate up […]